Contineum Therapeutics, Inc. Class A Common Stock CTNM · Stock Open Contineum Therapeutics, Inc. Class A Common Stock in new tab
Analyst price targets
Recent rating changes, newest first
Contineum Therapeutics, Inc. Class A Common Stock Analysis (CTNM)
Is Contineum Therapeutics, Inc. Class A Common Stock a good investment? Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is currently trading at 11.74 USD. Market analysts have a consensus price target of 20.33 USD. This suggests a potential upside from current levels.
Earnings Schedule: Contineum Therapeutics, Inc. Class A Common Stock is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -2.20.
Investor FAQ
Does Contineum Therapeutics, Inc. Class A Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Contineum Therapeutics, Inc. Class A Common Stock?
Contineum Therapeutics, Inc. Class A Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -2.25.
Company Profile
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Community Discussion